{
    "nct_id": "NCT03223103",
    "official_title": "Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)",
    "inclusion_criteria": "* Age ≥ 18\n* Confirmation of GBM (WHO grade IV).\n* Maximal debulking surgery and undergo radiotherapy concomitant with Temozolomide (45-70Gy)\n* Stable disease after treatment of radiation with chemotherapy\n* Life expectancy > 16 weeks.\n* Performance status of 0-2 (Eastern Cooperative Oncology Group).\n* First vaccine treatment start date at least 4 weeks out but not more than 8 weeks from the last dose of concomitant Temozolomide or radiotherapy.\n* Must have tumor tissue sufficient sequencing.\n* Have adequate bone marrow function\n* Require Dexamethasone ≤ 4mg daily on a stable dose\n* Acceptable hematologic, hepatic, and renal function and these tests must be performed within 14 days prior to study\n* The participant must be deemed competent to give informed consent.\n* The participant must agree to use two effective forms of contraception beginning at least four (4) weeks prior to study entry.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Progression of disease at time of screening.\n* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.\n* Infra-tentorial tumor or multifocal disease.\n* History of hypersensitivity reaction to Temozolomide.\n* Receiving any other investigational agents.\n* Prior history of unrelated neoplastic disease, and having received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation.\n* (HIV/AIDS), Chronic hepatitis B or hepatitis C.\n* History of, or is reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression.\n* History of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of: Vitiligo\n* Positive pregnancy test [45 CFR 46.203(b)]. (CFR = Code of Federal Regulations)",
    "miscellaneous_criteria": ""
}